NEW YORK, Sept. 19, 2016 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against American Renal Associates Holdings, Inc. (“American Renal Associates” or the “Company”) (NYSE:ARA) and certain of its officers. The class action is on behalf of a class consisting of all persons or entities who purchased American Renal Associates securities: (1) pursuant and/or traceable to American Renal’s Initial Public Offering on or about April 21, 2016 (the “IPO”); and/or (2) from April 21, 2016 through August 18, 2016, inclusive (the “Class Period”).
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that throughout the Class Period Defendants issued false and misleading statements to investors and/or failed to disclose that: (1) American Renal was engaged in a fraudulent scheme to steer patients away from qualified-for Medicare and Medicaid plans into more expensive Affordable Care Act plans to obtain greater reimbursement for American Renal’s dialysis services; (2) the foregoing scheme was in violation of federal and state laws; and (3) as a result, American Renal’s public statements were materially false and misleading at all relevant times.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/ara or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email [email protected]. Those who inquire by e-mail are encouraged to include their mailing address and telephone number. If you suffered a loss in American Renal Associates you have until October 31, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]


Chinese Universities with PLA Ties Found Purchasing Restricted U.S. AI Chips Through Super Micro Servers
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Nomura Upgrades PDD Holdings to Buy, Calls Stock Too Cheap to Ignore
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Cybersecurity Stocks Tumble After Anthropic's Claude Mythos AI Leak Sparks Market Fears
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
BlackRock CEO Larry Fink Earns $37.7 Million in 2025 Amid Record Growth
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 



